$1.65
+0.02 (+1.23%)
Open$1.62
Previous Close$1.63
Day High$1.66
Day Low$1.56
52W High$7.75
52W Low$1.47
Volume—
Avg Volume117.8K
Market Cap6.69M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,399.4% upside
Current
$1.65
$1.65
Target
$24.74
$24.74
$16.96
$24.74 avg
$28.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.58M | 4.80M | 3.77M |
| Net Income | 640.0K | 637.0K | 538.3K |
| Profit Margin | 14.0% | 13.3% | 14.3% |
| EBITDA | 1.20M | 1.08M | 968.7K |
| Free Cash Flow | 434.6K | 468.2K | 383.2K |
| Rev Growth | +11.7% | 0.0% | +15.1% |
| Debt/Equity | 0.17 | 0.18 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |